Eagle Genomics provides an AI-augmented knowledge discovery platform, e[datascientist], that empowers scientists to exploit multi-dimensional data to conduct science-led innovation. The system is powered by network science and multilayer hypergraphs and applies machine learning and AI to deliver data-driven insights and active learning across the microbiome innovation journey. It supports the entire innovation workflow from hypothesis through insight to product claims, helping bring novel, safer and sustainable products to market faster. The platform targets Food and Nutrition, Beauty and Personal Care, AgBio and BioPharma use cases. The company said the investment will support further development of e[datascientist], continued global expansion and the deepening of client impact. Eagle Genomics has sites in London’s Knowledge Quarter, Hyderabad (India), New York’s Genome Center, Paris’ Station F, Potsdam Science Park (Germany) and Kyiv (Ukraine). Eagle Genomics develops an AI-augmented knowledge discovery platform, e[datascientist]™, that applies network (graph) technology and Microsoft’s machine learning and cognitive services to microbiome and biology data. The platform is used by companies innovating in next-generation food, personal care, cosmetics and agritech products and is positioned to support science-backed product development. The company highlights a partnership history with Microsoft Genomics, becoming its first microbiome partner in 2018. Eagle Genomics operates in major genomics and AI centres including Cambridge’s Wellcome Genome Campus, London’s Knowledge Quarter, Microsoft’s AI Factory in Paris, Potsdam Science Park, JLABS in New York and HITEC City in Hyderabad. The business is led by CEO Anthony Finbow. It recently closed a $9M scale-up funding round to further develop platform capabilities and drive commercial expansion across Europe and the US. Eagle Genomics has developed a knowledge discovery platform that uses AI to analyze complex genomic and microbiomic data at scale. Its software delivers insights that help enterprise brands in consumer goods, agritech and healthcare assess product viability, efficacy and safety. Led by CEO Anthony Finbow, the company plans to use the funds to accelerate development of its software platform and to expand globally. Eagle Genomics intends to open international offices in Paris and New York to service the European and American markets. The company recently announced a partnership with Microsoft Genomics, which marked Microsoft’s first venture into the microbiome. Financially, Eagle Genomics raised $3.5m in a funding round led by the Environmental Technologies Fund, with participation from the UK Innovation & Science Seed Fund and Newable Private Investing. Eagle Genomics provides an AI-augmented knowledge discovery platform, the e[automateddatascientist], that transforms scientific data into actionable insights. The platform is positioned to help companies assess product potential, accelerate market entry and mitigate risk. The company plans to use recently raised funds to accelerate development of its knowledge discovery platform and to support sales and marketing activity. Leadership changes accompany the push: Anthony Finbow was appointed CEO and founder Abel Ureta-Vidal moved to Chief Product Officer. Financially, Eagle Genomics completed a bridge funding round in which it raised initial capital to advance product and commercial efforts. The company is preparing for a planned Series A toward the end of the year. Eagle Genomics is a Cambridge, UK-based bioinformatics specialist developing software solutions to enable pharmaceutical, biotech and personal care companies to reduce cost and time to complete research and bring new candidate medicines, therapies and products to patients and customers. Led by CEO Abel Ureta-Vidal, the company offers a range of software solutions that are already used by blue-chip clients such as Unilever. According to the article, Eagle Genomics raised £1m in funding. Backers included London Business Angels, the LBA EIS Roundtable Syndicate Fund 2016, and others. The company intends to use the funds to accelerate its marketing and product development activities. The article does not report operating metrics such as revenue or user numbers.

Total raised

$35M

Funding rounds

6

Latest round

Equity

Latest activity

Nov 2022